Drugs / Fluticasone/formoterol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04124510 | Nov 2019 → Sep 2020 | asthma | Mundipharma Korea Ltd | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluticasone/formoterol | “Fluticasone/formoterol (Flutiform®) shows a high fine particle fraction (FPF) of about 40% for both the ICS and the LABA components regardless the inhalation flow rate” NCT04124510 ↗ |
| Route | Inhaled | “dosage form: oral inhalation” NCT04124510 ↗ |